New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
07:22 EDTRPTP, OVAS, DRTX, EGLT, CORT, EBSJanney Capital to hold a conference
2nd Annual Healthcare 1x1 Corporate Access Day to be held in Boston on June 26.
News For RPTP;CORT;DRTX;EBS;EGLT;OVAS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 17, 2014
08:02 EDTDRTXActavis completes Durata Therapeutics tender offer
Subscribe for More Information
07:16 EDTOVASMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
November 13, 2014
07:30 EDTCORTCredit Suisse to hold a conference
Healthcare Conference is being held in Scottsdale, Arizona on November 10-13 with webcasted company presentations to begin on November 13 at 11 am; not all company presentations may be webcasted. Webcast Link
November 12, 2014
10:00 EDTOVASOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:13 EDTOVASBoston Biotech to hold a conference
Subscribe for More Information
07:10 EDTOVASOvaScience downgraded to Neutral from Outperform at Wedbush
Wedbush downgraded OvaScience to Neutral due to valuation.
06:06 EDTEGLTEgalet reports Q3 EPS (63c), consensus (77c)
Subscribe for More Information
November 10, 2014
07:48 EDTOVASOvaScience files $150M mixed securities shelf
Subscribe for More Information
07:32 EDTOVASOvaScience reports Q3 EPS (54c), consensus (45c)
Subscribe for More Information
07:29 EDTEBSEmergent BioSolutions seeks expanded BioThrax label
Emergent BioSolutions announced that it has submitted a supplemental Biologics License Application to the FDA seeking to expand the label of BioThrax to include a post-exposure prophylaxis indication. BioThrax, the only FDA-licensed vaccine to prevent anthrax disease, is currently licensed for a pre-exposure prophylaxis indication only. The company made a Request for Priority Review Designation to potentially reduce the anticipated approval of this application to six months. The sBLA proposes to expand the BioThrax indication to include a post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure when combined with the recommended course of antimicrobials in persons 18 through 65 years of age. The vaccination schedule consists of three doses of BioThrax administered at 0, 2, and 4 weeks post-exposure.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use